Table 1.
Patient characteristics and HPV circulating tumor DNA (HPV-ctDNA) detection
| Characteristics | All patients | HPV-ctDNA detectable at diagnosis | P |
|---|---|---|---|
| Total | 55 | 38 (69%) | |
| Age (years) | |||
| Median (range) | 50 (29-78) | 50 (29-78) | |
| FIGO stage | |||
| I | 5 (9%) | 1 (20%) | |
| II | 13 (24%) | 8 (62%) | 0.04 |
| III | 33 (60%) | 25 (76%) | |
| Iva | 4 (7%) | 4 (100%) | |
| Lymph node involvement | |||
| Yes | 33 (60%) | 27 (82%) | 0.02 |
| No | 22 (40%) | 11 (50%) | |
| Histology | |||
| SCC | 48 (87%) | 36 (75%) | 0.056 (SCCvsAdk) |
| Adenocarcinoma | 6 (11%) | 2 (33%) | |
| Other | 1 (2%) | 0 | |
| HPV type | |||
| HPV16 | 35 (64%) | 27 (77%) | 0.002 |
| HPV18 | 10 (18%) | 2 (20%) | |
| Other HPV (31, 33, 35, 45, 52, 58, 73) | 10 (18%) | 9 (90%) | |
| Tumor HPV copy | |||
| ≤5 copies/tumor cell | 26 (47%) | 16 (62%) | 0.381 |
| >5 copies/tumor cell | 29 (53%) | 22 (76%) | |
| Neoadjuvant chemotherapy | |||
| No | 46 (84%) | 32 (70%) | |
| Yes | 9 (16%) | 6 (67%) | |
| Brachytherapy | |||
| No | 19 (35%) | 13 (68%) | |
| Yes | 36 (65%) | 25 (69%) | |
| Surgerya,b | |||
| No | 36 (64%) | 28 (78%) | |
| Yes | 19 (35%) | 10 (53%) |
Adk, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papilloma virus; SCC, squamous cell carcinoma.
a
No surgery in the prospective cohort.
b
Five patients had surgery before chemoradiotherapy and 14 patients after.